

Market Announcement

17 June 2019

CardieX Limited (ASX: CDX) – Suspension from Official Quotation

Description

The securities of CardieX Limited ('CDX') will be suspended from quotation immediately under Listing Rule 17.2, at the request of CDX, pending the release of an announcement regarding a customer contract.

Issued by

Belinda Chiu

Senior Adviser, Listings Compliance (Sydney)



17 June 2019

Ms Belinda Chiu

By Email

To: belinda.chiu@asx.com ; tradinghaltssydney@asx.com.au

Dear Sir,

**RE: Request for Voluntary Suspension on Securities of CardieX Limited
(ASX: CDX CDXO)**

Pursuant to Listing Rule 17.2, pending an announcement regarding an update to a customer contract through CardieX investment company inHealth Medical Services, Inc, CDX formally applies for a voluntary suspension to be put in place immediately.

The suspension is requested to be in place until commencement of trade 18 June 2019 or when that announcement is released to the market.

CDX is not aware of any reason why the Company's request for a voluntary suspension should not be granted.

Yours sincerely,

CARDIEX LIMITED

A handwritten signature in blue ink, appearing to read "Jarrod White", written over the company name.

**JARROD WHITE
CHIEF FINANCIAL OFFICER | COMPANY SECRETARY**

For more information please contact:

Chief Financial Officer
Jarrod White
Ph: +61 8296 0000
jwhite@cardiex.com

Investor Relations
Peter Taylor
Ph: +61 412 036 231
peter@nwrcommunications.com.au

Cardiex

CardieX Limited is a global health technology company that develops digital and device-based solutions for large-scale population health disorders. The Company's XCEL device is the world leader in measuring "central blood pressure" which is considered essential for the management of hypertension and related cardiovascular disorders. CardieX also has a 50/50 joint venture partnership with Blumio, Inc in Silicon Valley for the development of a radar-based blood pressure sensor incorporating CardieX technology. In November 2018 CardieX entered into an agreement with telehealth services provider, inHealth Medical Services, Inc, allowing CardieX to acquire up to 50.5% of inHealth by way of a convertible note.